Keywords: Alexion, Taligen, Ophthalmic disease, Inflammatory pathways

Alexion acquires Taligen Therapeutics for $111 million

Article | 02 February 2011

Alexion Pharmaceuticals (Nasdaq: ALXN) says that it has acquired 100% of Taligen Therapeutics, a fellow USA-based privately held development-stage biotechnology company ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Alexion Pharmaceuticals

Go to company listing